Create Excellence in Pharmaceuticals; Enhance Innovation in China
Founded in 1995, Hansoh is a leading R&D-driven pharmaceutical company in China.
During the past two decades, Hansoh has been carrying the mission of "create excellence in pharmaceuticals, enhance innovation in China",Hansoh Pharma has been committed to improving human health through continuous innovation, especially in major disease treatment fields including oncology, CNS, anti-infectives and diabetes.
We have a proven track record of over 20 years of R&D experience. We have two R&D centers in Lianyungang and Shanghai and we have a dedicated professional research and development team staffed with more than 1,200 employees. We have several national-level R&D designations, including National Technology Center, Post-doctoral Research Station, and Key National Laboratory. We target to launch nearly 30 drug candidates by 2020, including 15 drug candidates with high growth potential, which comprise four candidates of Category 1.1 innovative drugs with NMEs and eight potential first-to-market generic drugs.
We have set up effective in-house sales force with therapeutic area focus and strong academic promotion capabilities. We have established world-class facilities and a manufacturing quality management system that complies with the cGMP requirements in China, the United States and Japan. Our manufacturing systems have obtained cGMP certifications from the U.S. FDA and the Japanese PMDA, and we plan to leverage our strong track record and experience to obtain additional quality system certifications and adopt advanced standards for entries into overseas markets. Our manufacturing quality management system enables us to produce all of our pharmaceutical products and the majority of our active pharmaceutical ingredients (APIs) in-house.
Our core management team has extensive pharmaceutical industry experience of pharmaceutical industry-related experience ranging from R&D to manufacturing to sales and marketing. The management team has in-depth knowledge and strong track record at all levels of the pharmaceutical industry value chain.
By setting faster pace in technology and innovation, striving to become a global R&D driven pharmaceutical company, leading the transformation of the industry, and fulfilling patients’ unmet clinical needs, Hansoh endeavors to make its own contribution to the “Healthy China 2030” master plan.